Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade D 19.43 2.75% 0.52
IMMU closed up 2.75 percent on Friday, November 16, 2018, on 1.33 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IMMU trend table...

Date Alert Name Type % Chg
Nov 16 Calm After Storm Range Contraction 0.00%
Nov 16 Lower Bollinger Band Walk Weakness 0.00%
Nov 16 Wide Bands Range Expansion 0.00%
Nov 16 Oversold Stochastic Weakness 0.00%
Nov 15 Stochastic Buy Signal Bullish 2.75%
Nov 15 Calm After Storm Range Contraction 2.75%
Nov 15 Lower Bollinger Band Walk Weakness 2.75%
Nov 15 Inside Day Range Contraction 2.75%
Nov 15 Wide Bands Range Expansion 2.75%
Nov 15 Lower Bollinger Band Touch Weakness 2.75%

Older signals for IMMU ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.33
52 Week Low 8.68
Average Volume 1,938,878
200-Day Moving Average 20.7356
50-Day Moving Average 21.7821
20-Day Moving Average 21.9678
10-Day Moving Average 21.2025
Average True Range 1.4206
ADX 22.41
+DI 16.9656
-DI 31.936
Chandelier Exit (Long, 3 ATRs ) 20.7282
Chandelier Exit (Short, 3 ATRs ) 21.5218
Upper Bollinger Band 25.7453
Lower Bollinger Band 18.1903
Percent B (%b) 0.16
BandWidth 34.391245
MACD Line -0.7203
MACD Signal Line -0.2098
MACD Histogram -0.5105
Fundamentals Value
Market Cap 2.16 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -13.22
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.52
Resistance 3 (R3) 21.37 20.53 21.17
Resistance 2 (R2) 20.53 20.00 20.60 21.05
Resistance 1 (R1) 19.98 19.67 20.26 20.13 20.94
Pivot Point 19.14 19.14 19.28 19.21 19.14
Support 1 (S1) 18.59 18.61 18.87 18.74 17.92
Support 2 (S2) 17.75 18.28 17.82 17.81
Support 3 (S3) 17.20 17.75 17.69
Support 4 (S4) 17.35